Ultragenyx Pharmaceuticals received a complete response letter from the U.S. Food and Drug Administration concerning its AAV-based gene therapy UX111 for Sanfilippo syndrome due to manufacturing concerns. The company remains confident that the issues are resolvable and that the therapy can eventually gain regulatory approval. This regulatory setback follows a previous FDA rejection, underscoring ongoing challenges in gene therapy manufacturing scale-up and quality control.